51 results about "Apoptotic body" patented technology

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

Synthetic and semisythetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed to trigger and apoptosis-like mechanism in the patient.

Conventional single fraction 20-Gy broadbeam photonbeam or protonbeam chemo-radiosurgery does not sterilize EMT-MET cancer stem cell radiodurans but single fraction 100 to 10,000 Gy microbeam radiosurgery sterilizes them. Device and methods for microbeam chemo-radiosurgery including 250 MeV wakefield electronbeam is disclosed.Surgery, chemotherapy and broadbeam and microbeam radiosurgery releases billions of abscopal metastasis causing, tumor specific plasma soluble proteins, cell membranes, apoptotic bodies, DNA and RNAs, exosomes like telomere-telomerase, ATM-ATM kinase and others. They and adaptive resistance to chemo-radiosurgery, paraneoplastic and non-paraneoplastic diseases causing immune complexes are removed by pulse flow combined continuous flow ultracentrifugation apheresis and immune affinity chromatography. Chemotherapy and high dose radiation exposed tumor cells and their exosomes are made sensitive to telomerase inhibiting and apoptosis inducing and least toxic epigallocatechin and to heparin bound receptors. They convert triple negative breast tumors into receptor positive tumors which open new avenues for treating most aggressive breast cancers.

The invention discloses a tumor-targeted delivery carrier based on cell-derived micro-vacuoles, a preparation method and an application. The preparation method comprises the following steps of: (A) preparing a conditioned medium: supplementing fetal bovine serum, antibiotics, DSPE-PEG-Biotin and DSPE-PEG-Folate into a basal medium; (B) using the obtained conditioned medium in cell culture, and collecting cell culture supernatant for subsequent separation; (C) carrying out low-speed centrifugation on the obtained culture supernatant to remove cell debris and apoptotic bodies, then adding SA-IONPs, mixing uniformly, incubating, then separating by a magnet, using PBS for re-suspension, eluting for multiple times to obtain the cell-derived micro-vacuoles with membrane surfaces modified by folic acid and iron oxide nano-particles, and freezing for storage; and (D) loading chemotherapeutic drugs or therapeutic genes into the functionalized micro-vacuoles doubly-modified by an electroporation mode, and carrying out re-suspension after separation with the magnet. The tumor-targeted delivery carrier based on cell-derived micro-vacuoles, the preparation method and the application disclosed by the invention are applicable to specific targeting delivery of multiple chemotherapeutic drugs and therapeutic genes, and have the advantages of enhancing the anti-tumor effect, reducing the systemic toxicity and improving the clinical effect of the current therapeutic selection, so that a new hope is brought for clinical therapy of tumors.

The invention relates to an application of Trichoderma pseudokoningii extracellular polysaccharides having anticancer activities. The Trichoderma pseudokoningii extracellular polysaccharides having the anticancer activities can reduce the vitality of K562 cells in vitro when they are applied to tumor growth inhibition (auxiliary) medicines, so intracellular active oxygen and free calcium ion concentrations are improved, the expression abundance of mRNA of p53 and Bax genes is improved, the expression of the Bc1-2 transcription level is reduced, the ectropion of cell membrane phosphatidylserine of the human chronic granulocyte leukemia cells K562 is induced, and the nuclear polycondensation and the fragmentation of K562 are induced to generate apoptotic bodies and apoptosis; and in-vivo administration can increase weights of tumor bearing mice and alleviate growth speeds and weights of tumors of the tumor bearing mice, thereby tumor cell killing and tumor growth inhibiting purposes are reached.

The present invention relates to methods of obtaining antigen-specific regulatory cells in vitro or in vivo. The regulatory cells are obtainable by inducing apoptosis of antigen-presenting cells by NKT cells. In particular, NKT cells are elicited, in vitro or in vivo, by exposure to CD1d-restricted NKT cell peptide epitopes either in natural configuration or modified as to contain a thioreductase motif within flanking residues. The present invention discloses methods to elicit immature antigen-presenting cells loaded with apoptotic cells or with apoptotic bodies for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are the use of antigen-specific regulatory cells for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are populations of antigen-specific regulatory cells obtained by this method.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)—RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

The invention provides an apoptotic body preserving solution and a method of long-term in-vitro preservation of an apoptotic body. The apoptotic body preserving solution is prepared from the followingcomponents: a cryoprotectant, an antioxidant and a buffer. According to the technical scheme, a stable apoptotic body source can be provided for stem cell therapy and beauty industry transformation.

The invention discloses an application of a mesenchymal stem cell apoptotic body to preparation of a medicine for treating bone defects, belongs to the technical field of biological medicines, and solves the problem that damaged bone cell repair and bone tissue regeneration cannot be fundamentally solved in the prior art. The invention provides the application of the mesenchymal stem cell apoptotic body to preparation of the medicine for treating bone defects. The invention also provides a medicinal preparation which comprises the mesenchymal stem cell apoptotic body and a pharmaceutically acceptable carrier. The inventor finds that the mesenchymal stem cell apoptotic body has the effects of promoting new bone formation and promoting bone regeneration for the first time, and has a good effect when being used for treating bone defects.

The invention relates to a cell microcapsule and a preparation method thereof, a cell microcapsule loaded with cancer resisting medicines, and a preparation method and application of the cell microcapsule loaded with cancer resisting medicines. The preparation method of the cell microcapsule comprises the following steps of (1) culturing immunocyte, and taking cell supernatant; (2) centrifuging the cell supernatant obtained in the step (1) to remove cells and cell fragments, and taking supernatant; (3) centrifuging the supernatant obtained in the step (2) to remove apoptotic bodies, and takingsupernatant, wherein the centrifuging condition includes that the centrifugal force is 2000-3000g, and the centrifuging time is 40-100min; and (4) centrifuging the supernatant obtained in the step (3), and taking precipitate. The preparation method is simple to operate, the cell microcapsule which is good in bioactivity, complete in structure, high in purity and uniform in particle diameter can be obtained; the obtained cell microcapsule can load liposoluble cancer resisting medicines through simple incubation, and the cell microcapsule is good in effects, good in targeting properties and lowin toxic and side effects when being used for preventing or treating cancer diseases.

The invention provides a new acellular matrix and a preparation method thereof. The preparation method comprises the following steps: preprocessing a tissue organ to be used, wherein the tissue organ to be used is a heterogeneous, or homogeneous xenogenous or autologous tissue organ; in culturing environment, exerting apoptosis induction factors on the tissue organ to be used so as to promote living cells to spontaneously form apoptotic bodies; eliminating the apoptotic bodies in the tissue organ to be used; cleaning the prepared acellular matrix. The method disclosed by the invention adopts a driving apoptotic cell removing manner, so that the destructive side effects of too much physical and chemical factors exerted by outside on extracellular matrix components are reduced, the spontaneous separation and degradation of cell components can also be effectively realized, and great convenience is brought for the elimination of subsequent cell components.

The invention provides preparation of broad spectrum antitumor mouse mold with apoptotic body vaccine immunity, wherein the mouse is prepared through the apoptotic body vaccine immunity and has the broad spectrum antitumor property. An establishment method includes: 1) in vitro, inducing apoptosis of cancer cells through a nutrient deficiency process to acquire the apoptotic body; 2) immunizing aKunming mouse with the apoptotic body by subcutaneous injection of 25 mg / kg of the apoptotic body to every mouse once per week, the injection lasting for five weeks in total. In vivo antitumor experimental results of the mouse prove that the anti-tumor rate on H22 tumor-bearing mice can reach 80.27% and model forming successful rate can reach 50%. The invention directs at problems that in a present experiment of immunizing antitumor animals, a positive control model is not reasonable and there is no broad spectrum immuno-antitumor mouse on market, whereas the mouse immunized by the apoptotic body solves the problem. The product has stronger antitumor immunity, is stable in model and is high in production quality.

The invention discloses an apoptotic body produced by inducing apoptosis of human umbilical cord mesenchymal stem cells in vitro and application thereof for promoting vascular regeneration of rats with myocardial infarction, and belongs to the field of regenerative medicine. At the same time, the invention also relates to a preparation method for obtaining the apoptotic body by inducing apoptosisof human umbilical cord mesenchymal stem cells in vitro. Experiments in vitro of the invention prove that the induction of apoptosis of umbilical cord mesenchymal stem cells can produce the apoptoticbody. At the same time, experiments in vivo prove that when the induced apoptotic body is used in the treatment of rats with myocardial infarction, the recovery of rat heart function and the vascularregeneration of damaged myocardium can be promoted. Therefore, the apoptotic body may become a potential effective agent for improving cardiac function after myocardial infarction.

The invention belongs to the technical field of liquid chromatographic separation, and particularly relates to a rapid and high-purity separation method of human plasma exosome. The method comprises the steps of firstly, removing apoptotic bodies and microvesicles of human plasma through high-speed centrifugation, then loading a sample to an agarose gel small column for pre-separation, and removing most of abundance proteins with relatively small sizes, such as human serum albumin and immune globulin; sequentially carrying out merging and ultrafiltration concentration on the collected fractions, and finally carrying out high performance liquid volume exclusion chromatography separation to realize separation of exosome and interference lipoprotein, thereby finally obtaining the high-purity human plasma exosome fraction. The whole process from plasma pretreatment to exosome fraction obtaining does not exceed two hours. Characterization of immunoblotting proves that the removal rate of high-density lipoprotein (HDL) can reach 95%, and the removal rate of low-density lipoprotein or very low-density lipoprotein (VHDL) can reach 85%.

The invention relates to tumor cell apoptotic bodies induced by a CO2 shock method and anti-tumor application of the tumor cell apoptotic bodies, wherein the tumor cell apoptotic bodies are obtained by placing tumor cells into a CO2-free incubator to cause apoptosis of the tumor cells. The tumor cell apoptotic bodies are collected by controlling single variables and utilizing separation and purification techniques, and in-vivo anti-tumor testing and in-vitro index detection can be simultaneously performed. The results show that the state and quantity of the collected apoptotic bodies are precisely grasped, and the collected apoptotic bodies have a strong anti-tumor effect.

The present invention relates to methods to elicit immature antigen-presenting cells loaded with apoptotic cells or apoptotic bodies. The present invention also relates to methods of obtaining antigen-specific regulatory T cells in vitro or in vivo. Cells loaded with apoptotic bodies / cells and regulatory T cells are obtainable by inducing apoptosis of antigen-presenting cells by cytolytic CD4+ T cells. The cells are used for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are the use of antigen-specific regulatory T cells for suppressing or preventing diseases such as autoimmune diseases, graft rejection and allergic diseases, and medicaments related thereto. Further disclosed are populations of antigen-specific regulatory T cells obtained by said method.

Synthetic and semisynthetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed to trigger an apoptosis-like mechanism in the patient.

The invention discloses a diagnosis and treatment integrated apoptotic body and a preparation method thereof. The preparation method comprises the following steps: culturing cells in a culture medium containing an antitumor drug and a nano contrast agent to obtain a culture medium of apoptotic cells; centrifuging the culture medium of apoptotic cells to obtain supernate; filtering the supernate to obtain filtrate; and centrifuging the filtrate to obtain a precipitate which is the diagnosis and treatment integrated apoptotic body. According to the invention, a nano-probe is carried on the mononuclear cells by utilizing the characteristic that the mononuclear cells in blood actively swallow apoptotic bodies; the in-vivo circulation time of the nano-probe is prolonged by actively avoiding interception and removal of a reticuloendothelial system through the mononuclear cells; and under recruitment of chemotactic factors released by tumor stem cells, the mononuclear cells carry anti-tumor drugs and contrast agents to actively permeate into a tumor infiltration area. The novel probe design thought gives full play to the unique advantages of autoimmune cells, and breaks through the traditional mode of 'contact type' recognition of targeted ligands and receptors.

The invention discloses application of apoptotic bodies in preparation of medicine for treating acute lung injury of mammals. Animal model experiments find that apoptotic body instillation can significantly improve the acute lung injury symptom of mice; after treatment, mouse alveolar macrophages are converted from a pro-inflammatory type to an anti-inflammatory type, so that the apoptotic body are expected to be used for treating human acute lung injury.

The invention provides application of FoF1-ATPasebeta protein in promotion or reduction of adsorption of cells on apoptotic bodies. An amino acid sequence of the FoF1-ATPasebeta protein contains a WalK A motif and a WalK B motif.

This invention relates to the use of tumor-derived or associated extracellular ribonucleic acid (RNA) found circulating in the plasma or serum fraction of blood for the detection, monitoring, or evaluation of cancer or premalignant conditions. Extracellular RNA may circulate as non-bound RNA, protein-bound RNA, lipid-RNA complexes, lipoprotein (proteolipid)-RNA complexes, protein-RNA complexes including within or in association with ribonucleoprotein complexes, nucleosomes, or within apoptotic bodies. Any intracellular RNA found in plasma or serum can additionally be detected by this invention. Specifically, this invention enables the extraction of circulating RNA from plasma or serum and utilizes nucleic acid amplification assays for the identification, detection, inference, monitoring, or evaluation of any neoplasm, benign, premalignant, or malignant, in humans or other animals, which might be associated with that RNA. Further, this invention allows the qualitative or quantitative detection of tumor-derived or associated extracellular RNA circulating in the plasma or serum of humans or animals with or without any prior knowledge of the presence of cancer or premalignant tissue.

Treatment and / or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and / or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and / or cells so formed to the patient.

The invention pertains to the field of the study of apoptosis, especially the field of the prognosis and monitoring of diseases wherein apoptosis occurs. Concretely, the invention relates to a method for isolating apoptotic bodies from a sample of body fluid, and to methods for the prognosis and evaluation of the efficiency of a treatment for vascular, neurodegenerative and / or oncological diseases, based on the use of said method for isolating apoptotic bodies.

Treatment and / or prophylaxis of endothelial dysfunction-related disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and / or apoptotic cells.

Provided is a functional chimeric apoptotic body. The functional chimeric apoptotic body comprises an apoptotic body membrane and mesoporous silica nanoparticles wrapped in the apoptotic body membrane, wherein the apoptotic body membrane is an apoptotic body membrane derived from immune cells, and the mesoporous silica nanoparticles are loaded with curcumin. An effective means is provided for constructing a specific treatment product with a targeted delivery function and an accurate drug release function.

Disclosed are compositions of matter useful for treatment of stroke derived from amniotic fluid stem cell produced factors. In one embodiment the invention teaches the use of products derived from amniotic fluid stem cells cultured under basal conditions. In another embodiment the invention teaches the utilization of amniotic stem cell derived products from said amniotic stem cells cultured under conditions of stress. Said amniotic stem cell derived products include small molecules, proteins, peptides, conditioned media, microvesicles, including exosomes and apoptotic bodies. In one embodiment, the invention teaches administration of amniotic fluid stem cells that have been exposed to a stress condition.

Provided is a functional chimeric apoptotic body. The functional chimeric apoptotic body comprises an apoptotic body membrane and mesoporous silica nanoparticles wrapped in the apoptotic body membrane, wherein the apoptotic body membrane is an apoptotic body membrane derived from immune cells, and the mesoporous silica nanoparticles are loaded with MicroRNA-21. An effective means is provided for constructing a specific treatment product with a targeted delivery function and an accurate drug release function.